Combination Therapy with Enzalutamide and Radium-223 in mCRPC: Insights from the REASSURE Study
					 / Igle Jan de Jong / Jan Andreasen				
				
			ESMO 2025: Paradigm Shift in Breast Cancer Treatment
					 / Charles E Geyer Jr.				
				
			ESMO 2025: Darolutamide-Treated mHSPC Patients Show a More Durable and Stronger PSA Response vs Abiraterone
					 / Alicia Morgans / Jan Andreasen				
				
			










